Ser303
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser303  -  TACSTD2 (human)

Site Information
VITNRRKsGKYKKVE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451171

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 1 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 1 )
Relevant cell line - cell type - tissue:
MTE4-14 ( 1 )

Upstream Regulation
Putative in vivo kinases:
PKCA (human) ( 1 )
Kinases, in vitro:
PKCA (human) ( 3 )
Treatments:
Go_6976 ( 1 ) , phorbol_ester ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on TACSTD2:
phosphorylation ( 1 ) , protein conformation ( 2 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 ) , cytoskeletal reorganization ( 1 )

References 

1

Guerra E, et al. (2022) Trop-2, Na/K ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion. Oncogene
35132180   Curated Info

2

Pavšič M, et al. (2015) The cytosolic tail of the tumor marker protein Trop2 - a structural switch triggered by phosphorylation. Sci Rep 5, 10324
25981199   Curated Info

3

Basu A, Goldenberg DM, Stein R (1995) The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer 62, 472-9
7635574   Curated Info